L Wang1, Y Shen. 1. The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, China. xlyb99@yahoo.com.cn
Abstract
BACKGROUND: Performance status is an attempt to quantify cancer patients' general well-being. This measure is used to determine whether they can receive chemotherapy. This study was to determine the expression of T-lymphocyte subpopulation in patients with gastric cancer and the relationship between T-lymphocyte subpopulation expression and patient performance status. METHODS: Flow cytometry was used to detect the T-lymphocyte subsets presented in peripheral blood in untreated patients with gastric cancer (n = 57) and healthy controls (n = 27). The gastric cancer patients were assessed with ECOG score and divided into two groups by score > 2 (n = 8) and score < or = 2 (n = 16). Spearman's rank correlation was used to determine the relationship between the proportion of T-lymphocytes and ECOG score. In addition, the clinical data of gastric cancer patients were Analyzed. RESULTS: The percentage of CD8+ and CD4+ T-cells among lymphocytes was higher and lower, respectively, in advanced gastric cancer patients than that in early gastric cancer patients (p < 0.05). Furthermore, the percentage of CD8+ and CD4+ cells among lymphocytes was higher and lower in advanced gastric cancer patients with PS > 2 and PS < or = 2, respectively (p < 0.05). However, no significant difference of CD8+ and CD4+ lymphocytes was found among the advanced gastric cancer patients with PS < or = 2, early gastric cancer patients, and healthy controls. CONCLUSIONS: Our results show that the determinants of the T-lymphocyte subpopulation in gastric cancer patients were of value in assessing performance status. We considered CD4+ and CD8+ T-lymphocytes to be a representative and stable parameter in quantifying cancer patients' general well-being, which could be used to determine whether they can receive chemotherapy and/or whether dose adjustment is necessary.
BACKGROUND: Performance status is an attempt to quantify cancerpatients' general well-being. This measure is used to determine whether they can receive chemotherapy. This study was to determine the expression of T-lymphocyte subpopulation in patients with gastric cancer and the relationship between T-lymphocyte subpopulation expression and patient performance status. METHODS: Flow cytometry was used to detect the T-lymphocyte subsets presented in peripheral blood in untreated patients with gastric cancer (n = 57) and healthy controls (n = 27). The gastric cancerpatients were assessed with ECOG score and divided into two groups by score > 2 (n = 8) and score < or = 2 (n = 16). Spearman's rank correlation was used to determine the relationship between the proportion of T-lymphocytes and ECOG score. In addition, the clinical data of gastric cancerpatients were Analyzed. RESULTS: The percentage of CD8+ and CD4+ T-cells among lymphocytes was higher and lower, respectively, in advanced gastric cancerpatients than that in early gastric cancerpatients (p < 0.05). Furthermore, the percentage of CD8+ and CD4+ cells among lymphocytes was higher and lower in advanced gastric cancerpatients with PS > 2 and PS < or = 2, respectively (p < 0.05). However, no significant difference of CD8+ and CD4+ lymphocytes was found among the advanced gastric cancerpatients with PS < or = 2, early gastric cancerpatients, and healthy controls. CONCLUSIONS: Our results show that the determinants of the T-lymphocyte subpopulation in gastric cancerpatients were of value in assessing performance status. We considered CD4+ and CD8+ T-lymphocytes to be a representative and stable parameter in quantifying cancerpatients' general well-being, which could be used to determine whether they can receive chemotherapy and/or whether dose adjustment is necessary.
Authors: Ali Raza Khaki; Ang Li; Leonidas N Diamantopoulos; Mehmet A Bilen; Victor Santos; John Esther; Rafael Morales-Barrera; Michael Devitt; Ariel Nelson; Christopher J Hoimes; Evan Shreck; Hussein Assi; Benjamin A Gartrell; Alex Sankin; Alejo Rodriguez-Vida; Mark Lythgoe; David J Pinato; Alexandra Drakaki; Monika Joshi; Pedro Isaacsson Velho; Noah Hahn; Sandy Liu; Lucia Alonso Buznego; Ignacio Duran; Marcus Moses; Jayanshu Jain; Jure Murgic; Praneeth Baratam; Pedro Barata; Abhishek Tripathi; Yousef Zakharia; Matthew D Galsky; Guru Sonpavde; Evan Y Yu; Veena Shankaran; Gary H Lyman; Petros Grivas Journal: Cancer Date: 2019-12-12 Impact factor: 6.921